Table 2.
Comparison of methylation of 7 miR CpG islands in 112 GC samples from patients with various clinicopathological characteristics
| Clinicopathological features |
miR-9-1 methylation |
miR-9-3 methylation |
miR-137 methylation |
miR-34b methylation |
miR-200b methylation |
miR-375 methylation |
miR-210 methylation |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive rate (%) | Proportion, Median * [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | Positive rate (%) | Proportion, Median [25-75%] | ||
| Age |
≤60 (n = 49) |
46.9a |
21 [14–38] |
68.8 |
35 [31–42] |
95.9 |
34 [16–48]b |
62.5 |
5 [2–16] |
92.9 |
49 [43–55] |
54.3 |
3 [2–14] |
65.1 |
9 [5–27] |
| |
>60 (n = 63) |
73.0 |
33 [18–44] |
61.0 |
36 [30–44] |
93.3 |
47 [29–61] |
54.2 |
10 [3–23] |
87.7 |
48 [40–56] |
38.3 |
3 [2–14] |
72.9 |
10 [5–17] |
| Sex |
Male (n = 80) |
61.2 |
31 [14–45] |
62.7 |
35 [30–42] |
96.1 |
40 [24–54] |
53.8 |
7 [3–18] |
88.4 |
48 [40–56] |
44.6 |
3 [2–7] |
69.9 |
9 [5–17] |
| |
Female (n = 32) |
62.5 |
27 [17–36] |
68.8 |
41 [30–43] |
90.6 |
43 [18–54] |
69.0 |
8 [2–26] |
93.3 |
51 [46–55] |
46.9 |
8 [2–19] |
69.0 |
12 [5–22] |
| Preoperative chemotherapy |
No (n = 100) |
63.0 |
32 [16–44] |
63.2 |
35 [30–43] |
93.8 |
39 [23–56] |
58.9 |
7 [3–18] |
91.0 |
49 [41–56] |
44.7 |
4 [2–16] |
69.6 |
9 [5–19] |
| Yes (n = 9) |
55.6 |
21 [12–31] |
66.7 |
37 [31–54] |
100 |
49 [30–53] |
44.4 |
5 [2–16] |
71.4 |
49 [42–76] |
44.4 |
2 [2–4] |
57.1 |
13 [10–24] |
|
| Location |
Cardiac (n = 34) |
64.7 |
37 [21–47] |
65.6 |
43 [35–51]b |
90.9 |
49 [28–61]b |
57.6 |
8 [3–23] |
75.0d |
43 [38–52] |
31.2 |
3 [1–8] |
64.5 |
9 [4–17] |
| |
Non-cardiac (n = 78) |
60.3 |
28 [14–42] |
64.0 |
34 [30–42] |
96.1 |
38 [20–52] |
58.1 |
6 [3–18] |
97.0 |
50 [42–56] |
51.4 |
3 [2–16] |
71.8 |
10 [5–21] |
| Differentiation |
Well/Mod. (n = 29) |
72.4a |
27 [9–44] |
69.0 |
37 [30–50] |
86.2 |
45 [31–53] |
44.4 |
9 [3–16] |
84.6 |
53 [42–58] |
40.7 |
3 [2–4] |
73.1 |
9 [4–17] |
| |
Poor (n = 78) |
56.4 |
31 [19–42] |
63.0 |
35 [30–42] |
97.3 |
38 [22–55] |
64.0 |
6 [3–19] |
91.3 |
48 [40–54] |
45.9 |
3 [2–14] |
66.2 |
10 [5–21] |
| Vascular embolus |
No (n = 60) |
65.0 |
26 [14–45] |
70.2 |
35 [31–43] |
89.7d |
45 [26–59] |
55.0 |
10 [3–19]c |
92.5 |
50 [42–57] |
51.7 |
3 [2–13] |
70.2 |
9 [5–20] |
| Yes (n = 49) |
59.2 |
31 [19–39] |
55.3 |
37 [30–43] |
100 |
39 [22–50] |
65.9 |
3 [2–11] |
86.0 |
48 [40–53] |
40.0 |
5 [2–20] |
66.7 |
11 [5–20] |
|
| pTNM stage |
I-II (n = 40) |
70.0 |
30 [14–47] |
67.6 |
37 [33–45] |
89.7d |
46 [35–59] |
59.0 |
10 [3–28]c |
91.9 |
49 [41–56] |
51.3 |
3 [2–8] |
64.1 |
9 [5–19] |
| |
III-IV (n = 59) |
59.3 |
30 [19–40] |
60.3 |
39 [32–43] |
100 |
40 [22–53] |
58.2 |
4 [2–17] |
87.8 |
49 [41–54] |
41.8 |
5 [2–20] |
70.0 |
12 [5–28] |
| Depth of invasion |
T1-2 (n = 25) |
68.0 |
34 [11–52] |
72.7 |
36 [31–44] |
84.0e |
48 [36–59] |
73.9 |
10 [3–21] |
86.4 |
52 [44–56] |
47.8 |
2 [2–4] |
70.8 |
9 [3–19] |
| T3 (n = 53) |
62.3 |
28 [17–41] |
58.5 |
35 [30–43] |
96.1 |
43 [28–53] |
49.0 |
7 [2–24] |
91.3 |
46 [36–56] |
48.0 |
5 [2–18] |
68.8 |
10 [5–18] |
|
| T4 (n = 25) |
60.0 |
30 [16–38] |
62.5 |
42 [33–44] |
100 |
31 [15–53] |
66.7 |
5 [2–17] |
90.9 |
49 [41–55] |
36.0 |
8 [3–20] |
66.7 |
14 [5–32] |
|
| Lymph node metastasis |
N0 (n = 57) |
68.4 |
26 [13–47] |
67.3 |
35 [32–43] |
89.1d |
45 [22–58] |
61.8 |
10 [3–20] |
90.6 |
53 [43–57]c |
46.4 |
2 [2–10] |
67.3 |
9 [5–19] |
| N1-3 (n = 51) |
56.9 |
31 [21–41] |
58.3 |
39 [30–44] |
100 |
39 [26–52] |
58.3 |
4 [2–16] |
88.1 |
45 [37–52] |
47.8 |
5 [2–20] |
69.8 |
11 [5–23] |
|
| Distant metastasis | M0 (n = 77) |
67.5a |
30 [14–44] |
64.4 |
37 [32–43] |
92.0 |
42 [24–56] |
60.0 |
8 [3–19] |
91.5 |
49 [41–56] |
46.7 |
3 [2–13] |
68.1 |
9 [5–17]c |
| M1 (n = 31) | 51.6 | 30 [21–40] | 60.0 | 36 [30–43] | 100 | 43 [24–53] | 60.7 | 6 [2–17] | 83.3 | 49 [40–53] | 48.1 | 6 [3–20] | 69.2 | 15 [9–28] | |
* %; [25-75%], 25%-75% percentiles; a, Pearson’s Chi-square test, miR-9-1 for age, differentiation, distant metastasis: χ2 = 7.924, 2.271, 2.402, and P = 0.005, 0.132, 0.121, respectively; b, Student t-test: miR-9-3 for location [42 ± 2 (Mean ± SD) vs 34 ± 1], t = 3.303, P = 0.002; miR-137 for age [34 ± 3 vs 44 ± 3], t = −2.651, P = 0.009; for location [46 ± 3 vs 37 ± 2], t = 2.103, P =0.038; c, Mann–Whitney U-test: miR-34b for pTNM stage/ vascular embolus, U = 239.000/320.000, P = 0.028/0.025, miR-200b for lymph node metastasis, U = 627.000, P = 0.021; miR-210 for distant metastasis, U = 301.000, P = 0.048; d, Fisher’s exact test: miR-137 for vascular embolus/pTNM/lymph metastasis, P = 0.031/0.024/0.028; miR-200b for location, P = 0.002; e,Trend test: miR-137 for depth of invasion, χ2 = 6.330, P = 0.012.